Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

The Acuvue Oasys Max 1-Day Multifocal marks the first and only daily disposable contact lens to be available for people with ...

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...

According to Sun Life, cancer is the most common and costly condition that its members face. Second opinions are important and can often play an important role in the decisions patients make in their ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...